

Hugh J Willison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5266086/publications.pdf>

Version: 2024-02-01

157
papers

13,067
citations

26630

56
h-index

24258

110
g-index

170
all docs

170
docs citations

170
times ranked

9512
citing authors

#	ARTICLE	IF	CITATIONS
1	Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. <i>Lancet, The</i> , 2016, 387, 1531-1539.	13.7	1,913
2	Guillain-Barré syndrome. <i>Lancet, The</i> , 2016, 388, 717-727.	13.7	1,076
3	Peripheral neuropathies and anti-glycolipid antibodies. <i>Brain</i> , 2002, 125, 2591-2625.	7.6	679
4	Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Annals of Neurology</i> , 2001, 50, 195-201.	5.3	577
5	Diagnosis and management of Guillain-Barré syndrome in ten steps. <i>Nature Reviews Neurology</i> , 2019, 15, 671-683.	10.1	463
6	Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. <i>Annals of Neurology</i> , 1999, 45, 168-173.	5.3	308
7	Serum antibodies to gangliosides in guillain-barré syndrome. <i>Annals of Neurology</i> , 1988, 23, 440-447.	5.3	257
8	The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. <i>Brain</i> , 2001, 124, 1968-1977.	7.6	254
9	Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 204-206.	1.9	232
10	Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. <i>Brain</i> , 2021, 144, 682-693.	7.6	221
11	Miller Fisher anti-GQ1b antibodies: ?-Latrotoxin-like effects on motor end plates. <i>Annals of Neurology</i> , 1999, 45, 189-199.	5.3	203
12	Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. <i>Brain</i> , 2008, 131, 1197-1208.	7.6	202
13	Monoclonal antibodies raised against Guillain-Barré syndrome-associated <i>Campylobacter jejuni</i> lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. <i>Journal of Clinical Investigation</i> , 1999, 104, 697-708.	8.2	198
14	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	7.6	190
15	Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after campylobacter infection. <i>Neurology</i> , 1997, 48, 717-724.	1.1	183
16	The immunobiology of Guillain-Barre syndromes. <i>Journal of the Peripheral Nervous System</i> , 2005, 10, 94-112.	3.1	167
17	Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. <i>Brain</i> , 2001, 124, 893-906.	7.6	166
18	Guillain-Barré syndrome: a century of progress. <i>Nature Reviews Neurology</i> , 2016, 12, 723-731.	10.1	153

#	ARTICLE	IF	CITATIONS
19	Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. <i>Brain</i> , 2010, 133, 1944-1960.	7.6	149
20	Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. <i>Muscle and Nerve</i> , 1988, 11, 1169-1176.	2.2	134
21	Immunolocalization of GQ1b and Related Gangliosides in Human Extraocular Neuromuscular Junctions and Muscle Spindles. , 2009, 50, 3226.		131
22	Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. <i>Brain</i> , 2012, 135, 1819-1833.	7.6	123
23	Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. <i>Brain</i> , 2004, 127, 2109-2123.	7.6	122
24	Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. <i>European Journal of Neurology</i> , 1999, 6, 71-77.	3.3	121
25	Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller fisher syndrome. <i>Journal of Neuroimmunology</i> , 1994, 50, 159-165.	2.3	115
26	Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. <i>Brain</i> , 1999, 122, 807-816.	7.6	114
27	Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy. <i>Journal of Neuroscience</i> , 2005, 25, 1620-1628.	3.6	111
28	Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. <i>Annals of Neurology</i> , 1995, 38, 111-118.	5.3	105
29	Infectious causes of acute flaccid paralysis. <i>Current Opinion in Infectious Diseases</i> , 2003, 16, 375-381.	3.1	105
30	Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 649-651.	1.9	104
31	Tolerance to Self Gangliosides Is the Major Factor Restricting the Antibody Response to Lipopolysaccharide Core Oligosaccharides in <i>Campylobacter jejuni</i> Strains Associated with Guillain-Barrel-Syndrome. <i>Infection and Immunity</i> , 2002, 70, 5008-5018.	2.2	103
32	Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. <i>Annals of Neurology</i> , 2005, 58, 203-210.	5.3	100
33	The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 595-610.	8.2	100
34	Complex Gangliosides at the Neuromuscular Junction Are Membrane Receptors for Autoantibodies and Botulinum Neurotoxin But Redundant for Normal Synaptic Function. <i>Journal of Neuroscience</i> , 2002, 22, 6876-6884.	3.6	98
35	Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. <i>Brain</i> , 2017, 140, 898-913.	7.6	92
36	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 68-76.	3.1	89

#	ARTICLE	IF	CITATIONS
37	A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18.. Journal of Clinical Investigation, 1996, 97, 1155-1164.	8.2	87
38	Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain, 2003, 126, 2220-2234.	7.6	85
39	Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain, 2003, 126, 2497-2509.	7.6	81
40	An open label clinical trial of complement inhibition in multifocal motor neuropathy. Journal of the Peripheral Nervous System, 2011, 16, 84-91.	3.1	80
41	Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. Journal of Physiology, 2009, 587, 3979-3999.	2.9	77
42	COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain, 2021, 144, 357-360.	7.6	77
43	Gangliosides and bacterial toxins in Guillain-Barré syndrome. Journal of Neuroimmunology, 1993, 46, 105-112.	2.3	74
44	Neuroinflammation in the peripheral nerve: Cause, modulator, or bystander in peripheral neuropathies?. Glia, 2016, 64, 475-486.	4.9	73
45	Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. The Cochrane Library, 2007, , CD004761.	2.8	72
46	Sialoadhesin Promotes Rapid Proinflammatory and Type I IFN Responses to a Sialylated Pathogen, <i>Campylobacter jejuni</i> . Journal of Immunology, 2012, 189, 2414-2422.	0.8	71
47	Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study. Journal of the Peripheral Nervous System, 2017, 22, 4-12.	3.1	70
48	Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. Lancet Neurology, The, 2020, 19, 826-839.	10.2	68
49	Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 1178-1183.	1.9	67
50	Acute motor neuropathy with antibodies to GM1 ganglioside. Journal of Neurology, 1991, 238, 447-451.	3.6	66
51	Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. Journal of Neuroimmunology, 2011, 238, 87-95.	2.3	66
52	Nodes, paranodes and neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 61-71.	1.9	60
53	Antibodies to Heteromeric Glycolipid Complexes in Guillain-Barré Syndrome. PLoS ONE, 2013, 8, e82337.	2.5	60
54	The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome. Journal of Neuroimmunology, 2008, 201-202, 172-182.	2.3	59

#	ARTICLE	IF	CITATIONS
55	Acute ataxic neuropathy with cross-reactive antibodies to GD _{1b} and GD ₃ gangliosides. <i>Neurology</i> , 1994, 44, 2395-2395.	1.1	59
56	Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy. <i>Muscle and Nerve</i> , 2000, 23, 164-174.	2.2	58
57	Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. <i>Brain</i> , 2003, 127, 680-691.	7.6	57
58	Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions. <i>Glia</i> , 2005, 52, 177-189.	4.9	57
59	Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. <i>Glycobiology</i> , 2009, 19, 789-796.	2.5	57
60	Current treatment practice of Guillain-Barré syndrome. <i>Neurology</i> , 2019, 93, e59-e76.	1.1	57
61	Glycolipid antigens and autoantibodies in autoimmune neuropathies. <i>Trends in Immunology</i> , 2013, 34, 453-459.	6.8	56
62	Zika virus tropism and interactions in myelinating neural cell cultures: CNS cells and myelin are preferentially affected. <i>Acta Neuropathologica Communications</i> , 2017, 5, 50.	5.2	56
63	Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. <i>Journal of Neuroimmunology</i> , 2008, 194, 181-190.	2.3	55
64	C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 23.	5.2	55
65	Cloning of human anti-GM1 antibodies from motor neuropathy patients. <i>Annals of Neurology</i> , 1994, 35, 471-478.	5.3	51
66	Mapping immunoreactive epitopes in the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies. <i>Acta Neuropathologica</i> , 1998, 95, 605-616.	7.7	51
67	Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. <i>European Journal of Neurology</i> , 2013, 20, 62-70.	3.3	50
68	Autoimmune responses in peripheral nerve. <i>Seminars in Immunopathology</i> , 1996, 18, 97-123.	4.0	46
69	Peripheral Neuropathy Associated with Anti-GM2 Ganglioside Antibodies: Clinical and Immunopathological Studies. <i>Autoimmunity</i> , 2000, 32, 133-144.	2.6	46
70	Autoimmune Neurological Conditions Associated With Zika Virus Infection. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 116.	2.9	46
71	Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neuropathy patients demonstrates diverse V region gene usage with extensive somatic mutation. <i>Journal of Immunology</i> , 1995, 155, 3049-59.	0.8	43
72	Neuronal Expression of GalNAc Transferase Is Sufficient to Prevent the Age-Related Neurodegenerative Phenotype of Complex Ganglioside-Deficient Mice. <i>Journal of Neuroscience</i> , 2014, 34, 880-891.	3.6	42

#	ARTICLE	IF	CITATIONS
73	Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. <i>Journal of Clinical Investigation</i> , 2012, 122, 1037-1051.	8.2	42
74	Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. <i>Brain</i> , 2021, 144, 3392-3404.	7.6	39
75	Solid phase immunoabsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. <i>Glycobiology</i> , 2007, 17, 294-303.	2.5	38
76	Mechanisms of Action of Anti-GM1 and Anti-GQ1b Ganglioside Antibodies in Guillain-Barré Syndrome. <i>Journal of Infectious Diseases</i> , 1997, 176, S144-S149.	4.0	37
77	Basic and clinical aspects of autoimmune disorders in peripheral nerves. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 14-18.	2.1	36
78	Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective. <i>Neurochemical Research</i> , 2002, 27, 697-709.	3.3	34
79	Characterisation of the immunoglobulin variable region gene usage encoding the murine anti-ganglioside antibody repertoire. <i>Journal of Neuroimmunology</i> , 2005, 165, 92-103.	2.3	34
80	CLINICAL EVALUATION AND INVESTIGATION OF NEUROPATHY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 3ii-8.	1.9	33
81	Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. <i>Current Opinion in Neurology</i> , 2016, 29, 572-580.	3.6	33
82	Anti-GQ1b antibodies and evoked acetylcholine release at mouse motor endplates. <i>Muscle and Nerve</i> , 2000, 23, 1035-1043.	2.2	32
83	Antiglycolipid antibodies, immunoglobulins and paraproteins in motor neuron disease: a population based case-control study. <i>Journal of the Neurological Sciences</i> , 1993, 114, 209-215.	0.6	31
84	Ganglioside complexes: new autoantibody targets in Guillain-Barré syndromes. <i>Nature Clinical Practice Neurology</i> , 2005, 1, 2-3.	2.5	31
85	Myelinj: an ImageJ macro for high throughput analysis of myelinating cultures. <i>Bioinformatics</i> , 2019, 35, 4528-4530.	4.1	30
86	Glial Sulfatides and Neuronal Complex Gangliosides Are Functionally Interdependent in Maintaining Myelinating Axon Integrity. <i>Journal of Neuroscience</i> , 2019, 39, 63-77.	3.6	30
87	Innate murine B cells produce anti-disialosyl antibodies reactive with <i>Campylobacter jejuni</i> LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes. <i>Journal of Neuroimmunology</i> , 2004, 152, 98-111.	2.3	29
88	Ganglioside antibodies and neuropathies. <i>Current Opinion in Neurology</i> , 2008, 21, 540-546.	3.6	27
89	Autoantibodies in immune-mediated neuropathies. <i>Current Opinion in Neurology</i> , 2012, 25, 550-555.	3.6	27
90	Motor nerve terminal destruction and regeneration following anti-ganglioside antibody and complement-mediated injury: An in and ex vivo imaging study in the mouse. <i>Experimental Neurology</i> , 2012, 233, 836-848.	4.1	27

#	ARTICLE	IF	CITATIONS
91	Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis. <i>Journal of the Peripheral Nervous System</i> , 2013, 18, 75-88.	3.1	27
92	Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis. <i>Brain</i> , 2016, 139, 1657-1665.	7.6	27
93	The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders. <i>Current Opinion in Chemical Biology</i> , 2014, 18, 78-86.	6.1	25
94	Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e284.	6.0	25
95	ZikaPLAN: Zika Preparedness Latin American Network. <i>Global Health Action</i> , 2017, 10, 1398485.	1.9	25
96	Zika virus infection in the returning traveller: what every neurologist should know. <i>Practical Neurology</i> , 2018, 18, 271-277.	1.1	25
97	Neuromuscular synaptic function in mice lacking major subsets of gangliosides. <i>Neuroscience</i> , 2008, 156, 885-897.	2.3	24
98	Guillain-Barré syndrome during the Zika virus outbreak in Northeast Brazil: An observational cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117272.	0.6	24
99	Sialylation of <i>Campylobacter jejuni</i> Lipo-Oligosaccharides: Impact on Phagocytosis and Cytokine Production in Mice. <i>PLoS ONE</i> , 2012, 7, e34416.	2.5	24
100	Heteromeric glycolipid complexes as modulators of autoantibody and lectin binding. <i>Progress in Lipid Research</i> , 2010, 49, 87-95.	11.6	23
101	Improving the detection of IgM antibodies against glycolipids complexes of GM1 and Galactocerebroside in Multifocal Motor Neuropathy using glycoarray and ELISA assays. <i>Journal of Neuroimmunology</i> , 2015, 278, 159-161.	2.3	23
102	Combinatorial Glycoarray. <i>Methods in Molecular Biology</i> , 2012, 808, 413-423.	0.9	23
103	Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. <i>Brain</i> , 2016, 139, 3041-3047.	7.6	22
104	Predicting Outcome in Guillain-Barré Syndrome. <i>Neurology</i> , 2022, 98, .	1.1	22
105	Perisynaptic Schwann cells phagocytose nerve terminal debris in a mouse model of Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 143-151.	3.1	21
106	Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 311-318.	1.9	21
107	Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With <i>Campylobacter jejuni</i> Infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	20
108	Gangliosides and Autoimmune Peripheral Nerve Diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 156, 355-382.	1.7	19

#	ARTICLE	IF	CITATIONS
109	Low sulfated heparins target multiple proteins for central nervous system repair. <i>Glia</i> , 2019, 67, 668-687.	4.9	18
110	Oligodendrocytes are susceptible to Zika virus infection in a mouse model of perinatal exposure: Implications for CNS complications. <i>Glia</i> , 2021, 69, 2023-2036.	4.9	17
111	Zika Virus Infection Leads to Demyelination and Axonal Injury in Mature CNS Cultures. <i>Viruses</i> , 2021, 13, 91.	3.3	17
112	EFNS Task Force Report: a questionnaire-based survey on the service provision and quality assurance for determination of diagnostic autoantibody tests in European neuroimmunology centres. <i>European Journal of Neurology</i> , 2000, 7, 625-628.	3.3	16
113	Neuromuscular synaptic transmission in aged ganglioside-deficient mice. <i>Neurobiology of Aging</i> , 2011, 32, 157-167.	3.1	16
114	The preâ€synaptic motor nerve terminal as a site for antibodyâ€mediated neurotoxicity in autoimmune neuropathies and synaptopathies. <i>Journal of Anatomy</i> , 2014, 224, 36-44.	1.5	16
115	Ranvier revisited. <i>Neurology</i> , 2014, 83, 106-108.	1.1	15
116	Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-BarrÃ© syndrome mouse model. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	15
117	Biomarkers in experimental models of antibodyâ€mediated neuropathies. <i>Journal of the Peripheral Nervous System</i> , 2011, 16, 60-62.	3.1	14
118	The translation of the pathological findings described in humans to experimental models of acute motor axonal neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 3-8.	3.1	14
119	ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas. <i>Global Health Action</i> , 2019, 12, 1666566.	1.9	13
120	Neuropathophysiological potential of Guillain-BarrÃ© syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals. <i>Clinical and Experimental Neuroimmunology</i> , 2011, 2, 59-67.	1.0	11
121	Guillain-BarrÃ© syndrome: surveillance and cost of treatment strategies â€“ Authors' reply. <i>Lancet, The</i> , 2017, 389, 253-254.	13.7	11
122	Anti-GQ1b ganglioside positive Miller Fisher syndrome â€“ evidence of paranodal pathology on nerve biopsy. <i>Journal of Neuromuscular Diseases</i> , 2014, 1, 191-195.	2.6	9
123	Glycoconjugates and Neuroimmunological Diseases. <i>Advances in Neurobiology</i> , 2014, 9, 543-566.	1.8	9
124	Asymptomatic dengue infection may trigger Guillainâ€BarrÃ© syndrome. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 375-377.	3.1	9
125	Sulfatide binding properties of murine and human antiganglioside antibodies. <i>Glycobiology</i> , 2007, 17, 1156-1166.	2.5	8
126	The Diagnostic Utility of Determining Anti-GM1: GalC Complex Antibodies in Multifocal Motor Neuropathy: A Validation Study. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 157-165.	2.6	8

#	ARTICLE	IF	CITATIONS
127	Progress in inflammatory neuropathy – the legacy of Dr Jack Griffin. <i>Nature Reviews Neurology</i> , 2015, 11, 646-650.	10.1	8
128	Heparanase attenuates axon degeneration following sciatic nerve transection. <i>Scientific Reports</i> , 2018, 8, 5219.	3.3	8
129	Anti-ganglioside Antibodies in Peripheral Nerve Pathology. <i>Methods in Molecular Biology</i> , 2018, 1804, 173-188.	0.9	8
130	SARM1 Depletion Slows Axon Degeneration in a CNS Model of Neurotropic Viral Infection. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 860410.	2.9	8
131	Differential binding patterns of anti-sulfatide antibodies to glial membranes. <i>Journal of Neuroimmunology</i> , 2018, 323, 28-35.	2.3	7
132	The role of gangliosides in the organisation of the node of Ranvier examined in glycosyltransferase transgenic mice. <i>Journal of Anatomy</i> , 2022, 241, 1259-1271.	1.5	7
133	Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective. <i>Frontiers in Immunology</i> , 2022, 13, 833548.	4.8	7
134	Anti-glycolipid antibodies in the diagnosis of autoimmune neuropathies. <i>Revue Neurologique</i> , 2002, 158, S16-20.	1.5	6
135	Prospective study comparing enzyme-linked immunosorbent assay and glycoarray assay to detect antiglycolipid antibodies in a routine diagnostic neuroimmunology laboratory setting. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 175-182.	1.0	5
136	A novel MT-CO2 variant causing cerebellar ataxia and neuropathy: The role of muscle biopsy in diagnosis and defining pathogenicity. <i>Neuromuscular Disorders</i> , 2021, 31, 1186-1193.	0.6	5
137	The legacy of ZikaPLAN: a transnational research consortium addressing Zika. <i>Global Health Action</i> , 2021, 14, 2008139.	1.9	5
138	Real time imaging of intra-axonal calcium flux in an explant mouse model of axonal Guillain-Barré syndrome. <i>Experimental Neurology</i> , 2022, 355, 114127.	4.1	5
139	The effects of age and ganglioside composition on the rate of motor nerve terminal regeneration following antibody-mediated injury in mice. <i>Synapse</i> , 2013, 67, 382-389.	1.2	4
140	Reply: Guillain-Barré syndrome, SARS-CoV-2 and molecular mimicry <i>and</i> Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barré syndrome <i>and</i> Unclear association between COVID-19 and Guillain-Barré syndrome <i>and</i> Currently available data regarding the potential association between COVID-19 and Guillain-Barré syndrome. <i>Brain</i> , 2021, 144, e47-e47.	7.6	4
141	Serum anti-GM2 and anti-GalNAc-CD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis. <i>Journal of Small Animal Practice</i> , 2021, , .	1.2	4
142	The Use of Myelinating Cultures as a Screen of Glycomolecules for CNS Repair. <i>Biology</i> , 2019, 8, 52.	2.8	3
143	Anti-GQ1b ganglioside positive Miller Fisher syndrome - evidence of paranodal pathology on nerve biopsy. <i>Journal of Neuromuscular Diseases</i> , 2014, 1, 191-195.	2.6	3
144	Multifocal Motor Neuropathy. <i>Practical Neurology</i> , 2002, 2, 298-301.	1.1	2

#	ARTICLE	IF	CITATIONS
145	Antibodies to GM1: galactocerebroside complexes in multifocal motor neuropathy: it takes two to tango. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 715-715.	1.9	2
146	Neuronally expressed α -series gangliosides are sufficient to prevent the lethal age-dependent phenotype in GM3-only expressing mice. <i>Journal of Neurochemistry</i> , 2021, 158, 217-232.	3.9	2
147	BAF45b Is Required for Efficient Zika Virus Infection of HAP1 Cells. <i>Viruses</i> , 2021, 13, 2007.	3.3	2
148	Involvement of cation channels in autoimmune disease. <i>Biochemical Society Transactions</i> , 1994, 22, 488-491.	3.4	1
149	Anti-Q1b antibodies and evoked acetylcholine release at mouse motor endplates. <i>Muscle and Nerve</i> , 2000, 23, 1035-1043.	2.2	1
150	Diagnosis and management of Guillain-Barré syndrome in ten steps. , 0, .		1
151	Detection of Autoantibodies Using Combinatorial Glycolipid Microarrays. <i>Methods in Molecular Biology</i> , 2022, 2460, 183-191.	0.9	1
152	Use of Anti-Nerve Antibodies. , 0, , 87-93.		0
153	Reply: Neurofascin as target of autoantibodies in Guillain-Barre syndrome. <i>Brain</i> , 2011, 134, e174-e174.	7.6	0
154	Autoantibodies to Glycolipids in Peripheral Neuropathy. , 2016, , 961-965.		0
155	Diretrizes Baseadas em Evidências Diagnóstico e manejo da Síndrome de Guillain-Barré em dez etapas. <i>Revista Neurociencias</i> , 0, 29, 1-52.	0.0	0
156	The elusive diagnosis of sensory neuronopathy. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 449-450.	0.8	0
157	Commentary. <i>Journal of Neurosciences in Rural Practice</i> , 2014, 5, 65-7.	0.8	0